Main Article Content
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. Cohoon KP, De Sanctis Y, Haskell L, et al. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018;16:1278-1287.
3. Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017;117(09):1662-1670.
4. Mahan CE, Burnett AE, Fletcher M, et al. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization – a paradigm shift in post-discharge thromboprophylaxis. Hosp Prac. 2017;46(1):5-15.
5. Cohen AT, Harrington RA, Goldhaber SZ, et al. Prevalence of major medical illnesses associated with venous thromboembolism risk in US hospitals. Res Pract Thromb Haemost. 2017;1(Suppl 1):1-1451.
6. Mahan CE, Fisher MD, Mills RM, et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res. 2013;132:520-526.
7. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464-474.
8. Heit JA, Mohr DN, Silverstein MC, et al. Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism. Arch Intern Med. 2000;160(6):761-768.
9. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for DVT Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.
10. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376:1211-1222.
11. National Transitions of Care Coalition. Improving DVT/PE Transitions of Care. http://www.ntocc.org/AboutUs/KnowledgeResourceCenter/tabid/144/Default.aspx (accessed Sep 13, 2019).
12. Giustozzi M, Franco L, Vedovatic MC, et al. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis. doi: 10.1007/s11239-029-01878-x (published 18 May 2019).
13. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. N Engl J Med. 2013;386:513-523.
14. Spyropoulos AC, Cohen AT, Lipardi C, et al. Abstract 10541: Improved Benefit Risk Profile of Rivaroxaban in a MARINER-Like Subpopulation of the MAGELLaN Study. Circulation. 2018;138:A10541.
15. Spyropoulos AC, Cohen AT, Lipardi C, et al. Improved Benefit Risk Profile of Rivaroxaban in a MARINER-Like Subpopulation of the MAGELLaN Study. Poster presented at American Heart Association Scientific Sessions. Chicago, IL; 2018 Nov 10.
16. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. N Engl J Med. 2011;365:2167-2177.
17. Hull RD, Schellong SM, Tapson VF, et al. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility. Ann Intern Med. 2010;153(1):8-18.
18. Bevyxxa (betrixaban) package insert. San Francisco, CA: Portola Pharmaceuticals, Inc; 2017 Jun.
19. Cohen AT, Harrington RA, Goldhaber SZ, et al. (2016) Extended Thromboprophylaxis with Betrixiban in Acutely Ill Medical Patients. N Engl J Med. 2016;375:534-544.